Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Graves' Disease
NCT00150111Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Jun 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in Graves' disease and thyroid associated ophthalmopathy (TAO) (2 arms), sponsored by University Hospital Odense. Primary endpoint: Time to relapse after cessation of treatment at 12 months. Started Jun 2003; status: completed.
02
Drugs
rituximab
03
Conditions
Graves' diseasethyroid associated ophthalmopathy (TAO)
Beyond the preview
Go deeper on NCT00150111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00150111.